Quest Diagnostics Incorporated $DGX Shares Sold by SVB Wealth LLC

SVB Wealth LLC lessened its position in shares of Quest Diagnostics Incorporated (NYSE:DGX) by 25.8% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 12,869 shares of the medical research company’s stock after selling 4,479 shares during the quarter. SVB Wealth LLC’s holdings in Quest Diagnostics were worth $2,522,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Quattro Advisors LLC acquired a new stake in Quest Diagnostics during the fourth quarter worth $25,000. JFS Wealth Advisors LLC increased its position in shares of Quest Diagnostics by 114.3% during the 4th quarter. JFS Wealth Advisors LLC now owns 150 shares of the medical research company’s stock worth $26,000 after purchasing an additional 80 shares during the last quarter. Sittner & Nelson LLC purchased a new stake in Quest Diagnostics in the 4th quarter valued at about $29,000. DV Equities LLC acquired a new position in Quest Diagnostics in the fourth quarter valued at about $27,000. Finally, Harbor Investment Advisory LLC lifted its position in Quest Diagnostics by 113.7% in the fourth quarter. Harbor Investment Advisory LLC now owns 156 shares of the medical research company’s stock valued at $27,000 after buying an additional 83 shares during the last quarter. 88.06% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, CEO J. E. Davis sold 10,000 shares of the business’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $194.14, for a total transaction of $1,941,400.00. Following the completion of the transaction, the chief executive officer directly owned 132,423 shares of the company’s stock, valued at $25,708,601.22. The trade was a 7.02% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Karthik Kuppusamy sold 8,147 shares of the stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $200.00, for a total value of $1,629,400.00. Following the completion of the sale, the senior vice president directly owned 13,510 shares in the company, valued at $2,702,000. This represents a 37.62% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 0.88% of the company’s stock.

Quest Diagnostics Price Performance

Shares of DGX opened at $193.70 on Tuesday. Quest Diagnostics Incorporated has a fifty-two week low of $164.65 and a fifty-two week high of $213.50. The firm’s 50 day moving average price is $194.90 and its 200 day moving average price is $192.27. The company has a market cap of $21.44 billion, a P/E ratio of 21.40, a PEG ratio of 2.32 and a beta of 0.59. The company has a quick ratio of 1.08, a current ratio of 1.18 and a debt-to-equity ratio of 0.67.

Quest Diagnostics (NYSE:DGX) last issued its quarterly earnings results on Tuesday, April 21st. The medical research company reported $2.50 EPS for the quarter, beating the consensus estimate of $2.37 by $0.13. The company had revenue of $2.90 billion during the quarter, compared to analysts’ expectations of $2.83 billion. Quest Diagnostics had a net margin of 9.07% and a return on equity of 15.60%. The firm’s revenue was up 9.2% compared to the same quarter last year. During the same quarter last year, the company posted $1.94 EPS. Quest Diagnostics has set its FY 2026 guidance at 10.630-10.830 EPS. On average, research analysts forecast that Quest Diagnostics Incorporated will post 10.72 earnings per share for the current fiscal year.

Quest Diagnostics Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, July 22nd. Investors of record on Wednesday, July 8th will be issued a $0.86 dividend. The ex-dividend date is Wednesday, July 8th. This represents a $3.44 dividend on an annualized basis and a yield of 1.8%. Quest Diagnostics’s dividend payout ratio (DPR) is 38.01%.

Analyst Ratings Changes

DGX has been the topic of a number of research analyst reports. Wall Street Zen raised shares of Quest Diagnostics from a “hold” rating to a “buy” rating in a research note on Saturday. Robert W. Baird lifted their target price on shares of Quest Diagnostics from $224.00 to $229.00 and gave the company a “neutral” rating in a report on Wednesday, April 22nd. UBS Group boosted their target price on Quest Diagnostics from $210.00 to $220.00 and gave the company a “neutral” rating in a research report on Wednesday, April 22nd. Truist Financial upped their price target on Quest Diagnostics from $220.00 to $225.00 and gave the stock a “hold” rating in a research note on Wednesday, April 22nd. Finally, Jefferies Financial Group restated a “buy” rating and set a $225.00 price target on shares of Quest Diagnostics in a research report on Tuesday, April 21st. Seven equities research analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $216.58.

About Quest Diagnostics

Quest Diagnostics (NYSE: DGX) is a leading provider of diagnostic information services that supports clinical decision-making for patients, physicians and healthcare organizations. The company operates a network of clinical laboratories and patient service centers that perform a broad range of laboratory tests and diagnostic assays used in routine care, disease diagnosis, monitoring and screening.

Its services span core clinical laboratory testing, anatomic pathology, molecular and genomic diagnostics, infectious disease testing and toxicology.